Mechanisms through which BMSCs decrease the sensitivity of myeloma cells to drug treatments include the secretion of cytokines such as interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) [24,50], and cell-to-cell contacts [5]. The gene discussed is VEGFA; the disease is plasma cell myeloma.